NCT07793396Recruiting
Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures
A Prospective, Real-World Evidence, Multicenter Study to Evaluate the Efficacy and Safety of Eslicarbazepine in Managing Epilepsy
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice. Participants will include newly diagnosed patients and patients previously treated with carbamazepine or oxcarbazepine who have inadequate seizure control or intolerable adverse effects. Treatment with eslicarbazepine will be initiated or changed at the discretion of the treating physician in accordance with routine clinical practice. Participants will be followed for 3 months.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1500 (estimated)
- First submitted
- 25 Aug 2026
- Start date
- Dec 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- King Edward Medical University
- Diseases
- Epilepsy
- NCT number
- NCT07793396
What you commit to
- Study type: Observational
- Planned participants: 1500
- From Dec 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have a contraindication to the medicine or any component of prescribed therapy.
Other illness
- Any hypersensitivity to Eslicarbazepine.
Other
- Female patients who are pregnant or lactating.
Who the study is looking for
- Adult patients (aged at least 18 years) with diagnosed partial-onset seizures.
- Newly diagnosed (treatment-naïve) or previously treated with Carbamazepine or Oxcarbazepine and inadequately controlled or intolerant.
- Patient or Legal Representative is willing and able to provide informed consent, or, in the absence of a legal representative, an Independent Healthcare Professional provides authorization for patient enrolment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Hospital Lahore Coordinator of this site? Confirm its status | Lahore | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.